ArticleEuropean journal of epidemiology2026
Cohort update: waves 2 and 3 of the global flourishing study.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The global flourishing study is a longitudinal panel study designed to advance research on human flourishing across culturally and geographically diverse contexts. wave 1 included more than 200,000 adults from 21 countries and one territory, recruited to be approximately nationally representative of adult (18 +) populations. The initial cohort profile detailed the wave 1 sampling design and implementation. In this cohort profile update, we describe major developments since the original profile was published, including a mid-year retention survey, completion of wave 2 data collection, and inclusion of mainland China data. We summarize attrition patterns across countries, methodological refinements, and potential research applications. These include high variation in retention rates across countries, ranging from 90% in mainland China to 23.5% in Hong Kong, with an overall retention rate of 62%. The overall retention rate at wave 3 overall retention rate of 53.6%. Retention rates for Wave 3 range from 85.3% in mainland China to 12.9% in Hong Kong. The follow-up strategy of recontacting all Wave 1 participants led to the inclusion of ~ 14,000 who did not respond in Wave 2 but did respond in Wave 3. Key strengths of the global flourishing study include its multinational scope, longitudinal design, representative sampling, and open data access, while limitations include reliance on self-reports and variability in some aspects of the methodology across samples (e.g., differences in timing of data collection and weighting approaches). Key limitations of the global flourishing study include the variation and sometimes high attrition rates across some countries, heterogeneity in the length of time between waves, and potential survey mode effects. Beyond a continued commitment to open science, future directions of the global flourishing study include expanding to subsequent waves and the potential addition of new countries and item modules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.